BAM
CRMD icon

Bruderman Asset Management’s CorMedix CRMD Stock Holding History

Bruderman Asset Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-400
Closed -$8K – 426
2015
Q2 		$8K Buy
+400
New +$13.7K ﹤0.01% 364

Other funds holding CRMD

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Bruderman Asset Management's CRMD Position: Q3 2015 in Review

Bruderman Asset Management sold out of CorMedix (CRMD) in Q3 2015, closing a stake of 400 shares — an estimated $8K sold.

Bruderman Asset Management first reported a position in CRMD in Q2 2015 and held it in 1 quarter. The position peaked at $8K in Q2 2015. 54 funds tracked by Wall St. Rank hold CRMD as of Q3 2015.

  • Bruderman Asset Management reported no remaining CorMedix position as of Q3 2015 after selling out during the quarter.
  • Bruderman Asset Management sold 400 CorMedix shares in Q3 2015, an estimated $8K.
  • Bruderman Asset Management first reported a position in CorMedix in Q2 2015 and held it in 1 quarter.
  • Bruderman Asset Management's CorMedix position peaked at $8K in Q2 2015.
  • 54 funds tracked by Wall St. Rank held CorMedix as of Q3 2015.

Based on Bruderman Asset Management's 13F filing for Q3 2015, filed 19 Nov 2015.